Gilead (GILD) Rips Following GS-7977 Update
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Join SI Premium – FREE
Gilead Sciences (Nasdaq: GILD) is ripping pre-market Thursday following an update on its proposed treatment for genotype 1 chronic hepatitis C virus (HCV) infection, GS-7977.
According to the release, "the study found that 90 percent of patients (n=47/52, missing data equals failure analysis) achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load (HCV RNA <25 IU/mL) 12 weeks after the completion of therapy."
Shares are up over 14 percent early. For more color on the release, click here.
According to the release, "the study found that 90 percent of patients (n=47/52, missing data equals failure analysis) achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load (HCV RNA <25 IU/mL) 12 weeks after the completion of therapy."
Shares are up over 14 percent early. For more color on the release, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) call put ratio 1 call to 1.1 puts into quarter results
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Gilead Sciences (GILD) call put ratio 3.2 calls to 1 put into quarter results
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
